Repurposing the selective oestrogen receptor modulator tamoxifen for the treatment of duchenne muscular dystrophy

7Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Drug discovery is a long, expensive and risky process. Evaluating drugs that have already been proved safe for use in humans and testing them for a new indication greatly reduces the time and monetary costs involved in finding treatments for life-threatening conditions. Here tamoxifen, a drug that is used for the treatment of breast cancer, is investigated in a mouse model of Duchenne muscular dystrophy. Tamoxifen was efficacious in countering the symptoms of the disease without affecting the underlying genetic cause. Based on these results, tamoxifen has been tested in other forms of muscle disease with success. Drug repurposing may not only be a cost-effective manner for treating a variety of diseases, it may also help us uncover common mechanisms between conditions that were previously thought to be unrelated.

Cite

CITATION STYLE

APA

Gayi, E., Neff, L. A., Ismail, H. M., Ruegg, U. T., Scapozza, L., & Dorchies, O. M. (2018). Repurposing the selective oestrogen receptor modulator tamoxifen for the treatment of duchenne muscular dystrophy. In Chimia (Vol. 72, pp. 238–240). Swiss Chemical Society. https://doi.org/10.2533/chimia.2018.238

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free